Honest dosage

Three Milligrams Of Gymnema: What A Token Row Is For

Two rows on this panel are three milligrams. The trials behind both used amounts between a hundred and a thousand times larger. That is worth explaining rather than either hiding or shouting about, because a small declared row is not the same thing as a dishonest one.

By Evo Slim Team · Last updated October 29, 2026 · 9 min read · Honest dosage · Reviewed by Dr. Pascale Carbonara, MD

The two three-milligram rows

Thirteenth and seventeenth on the panel: Gymnema Extract (leaf) 3 mg, and White Mulberry Extract (leaf) 3 mg. Both are printed, both are declared, and neither is hidden inside a blend.

Three milligrams is a very small amount of anything. For scale, a grain of table salt is about 0.06 mg, so three milligrams is roughly fifty grains. Held in the hand it would be invisible against the 125 mg of magnesium sitting beside it in the same capsule.

The question this post exists to answer is not whether that is a lot. It obviously is not. The question is what a row like that is doing on a label, and whether printing it is better or worse than not printing it at all.

What the ratio actually is

Left-hand figures are read off the label artwork. Right-hand figures belong to the trials cited on the ingredients page, not to this capsule.

Read down the right-hand column and the pattern is the same one every twenty-row capsule produces: the botanical rows sit at roughly one to five per cent of their researched amounts, and the mineral row sits at somewhere between a seventh and a third.

That is not a scandal. It is arithmetic. A capsule holds a few hundred milligrams of powder in total, and twenty rows inside that ceiling cannot each be a trial dose. Any twenty-row product on any shelf faces the identical constraint.

Why a token row exists at all

Four reasons, and they are not equally respectable.

Four reasons, and only the last one is a problem. This label does not do the last one: the bottle makes a single structure-and-function claim and names no trial.

The third reason is the honest one and it is usually the real one. The first is legitimate as long as the label does not pretend to be doing the second thing. The second is commercial and a page like this one should say so out loud.

The fourth is the one that turns a small row into a lie, and it happens by implication rather than by statement: name an ingredient, put a study logo near it, and let a reader assume the study's result travelled with the name. The NIH review of weight-related supplements describes that pattern across the whole category.

When it is defensible and when it is not

• Defensible: the amount is printed, the row is not inside a blend, and the label makes no claim that depends on the amount being larger.
• Defensible: the ingredient is there for breadth and the product is sold as a broad daily base, which is what a twenty-row capsule actually is.
• Not defensible: the amount is hidden inside a proprietary blend, so nobody can tell whether it is three milligrams or three hundred.
• Not defensible: a trial is named or shown beside a row that carries one per cent of the trial's dose.
• Not defensible: the front of the bottle promises an outcome that only the trial dose was ever tested against.

By that test this label is on the defensible side of all five. Every amount is printed, there is no blend, the bottle prints one structure-and-function claim, and no study is named or implied anywhere on the packaging. The criticism available is about dose fidelity, and this desk makes it on its own home page rather than leaving it to somebody else.

Gymnema, and the part a capsule cannot do

Gymnema sylvestre is genuinely interesting, and the interesting part is one a capsule cannot deliver at any dose.

The plant contains gymnemic acids, which temporarily block sweet taste receptors on the tongue. Chew a leaf and sugar tastes of nothing for a quarter of an hour, which is a real and startling effect. It requires contact with the tongue, and a swallowed capsule has none.

The swallowed research is a different question and a more modest one. The pooled trials of glycaemic control used 200 to 400 mg a day of leaf extract and found modest effects; a later review covering body measurements looked at the anthropometric outcomes as well. Three milligrams is not in that conversation in either direction.

What that means in practice

If sweet-taste suppression is the thing you read about and wanted, this is not the format for it, and nothing about the amount would fix that. If you want a broad daily capsule that includes gymnema among nineteen other declared rows, this is exactly that, and the label says so without decoration.

Mulberry, and the unit problem

White mulberry has the same shape of story with a different twist in it, and the twist is about units.

The compound behind mulberry leaf's reputation is 1-deoxynojirimycin, which slows the digestion of starch. The 2007 human study used food-grade mulberry powder enriched with it, at 0.8 to 1.2 grams per dose. A later dose-finding trial went higher still, using grams of leaf powder three times a day.

Three milligrams of an unstandardised extract cannot be compared with either, because the extract's concentration is not printed and because three milligrams is a thousandth of a gram whatever the concentration turns out to be.

What this desk thinks, said plainly

These two rows are the weakest part of this label, and it is better to say that here than to have a reader find it themselves and wonder what else was smoothed over.

The product they belong to is a broad daily capsule with complete disclosure and a simple routine, sold with a sixty-day window counted from purchase. That is a coherent thing to buy and this desk is happy to sell it. It is not a stack of researched doses and nobody should buy it believing that it is.

Anyone who wants the second thing should buy a single-ingredient product at a researched amount, read the trials, and give it the same eight weeks. That advice costs this desk a sale and it is the right advice.

What would change this assessment

Two things, and neither requires a new trial. A standardisation percentage on the gymnema and mulberry rows would at least make the amounts calculable, which is the difference between a small known quantity and an unknown one. And a shorter panel at larger amounts would trade breadth for testability, which is a legitimate product decision that some manufacturers take.

Neither is likely on a twenty-row capsule, because breadth is what a twenty-row capsule is for. But naming the version of this product that would score better is more useful than complaining about the version that exists, and it is the standard this desk would want applied to anything it sells.

The row-by-row version, with every trial amount printed beside every label amount, is on the ingredients page. The nine-point checklist this product is scored against in public is on the choosing a formula page.

References